NASDAQ:PEPG PepGen Q2 2026 Earnings Report $2.85 -0.12 (-4.04%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$2.86 +0.02 (+0.53%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast PepGen EPS ResultsActual EPS-$0.26Consensus EPS -$0.28Beat/MissBeat by +$0.02One Year Ago EPSN/APepGen Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APepGen Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateThursday, August 6, 2026Conference Call Time7:00AM ETUpcoming EarningsPepGen's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) PepGen Earnings HeadlinesPepGen Inc. (PEPG) Interactive Stock Chart - Yahoo FinanceSeptember 16, 2026 | finance.yahoo.comPepGen, Inc. (NASDAQ:PEPG) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 15, 2026 | americanbankingnews.comThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this supercycle - and says that may be conservative. Billionaire Pierre Lassonde has argued for $19,000. Former CIA advisor Jim Rickards targets $27,000 based on a federal revaluation of the gold supply. But the bigger opportunity may not be gold itself. A 'backdoor' gold-linked asset has historically multiplied gold's move by 10x or more - returning 846%, 1,668%, 1,847%, and 1,915% in the last supercycle.September 20 at 1:00 AM | Traders Agency (Ad)PepGen (NASDAQ:PEPG) Earns Buy Rating from HC WainwrightSeptember 11, 2026 | americanbankingnews.comDSMB approves dose escalation in PepGen’s FREEDOM2-DM1 studyAugust 7, 2026 | msn.comPepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB ReviewAugust 6, 2026 | businesswire.comSee More PepGen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PepGen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PepGen and other key companies, straight to your email. Email Address About PepGenPepGen (NASDAQ:PEPG) Inc. (NASDAQ: PEPG) is a clinical-stage biopharmaceutical company focused on developing medicines for patients with neuromuscular and other serious diseases. The company’s platform is designed to use cell-penetrating peptides to enhance the delivery of oligonucleotide therapeutics into muscle and other tissues. PepGen’s development programs include PGN-EDO51, an investigational exon-skipping therapy being developed for Duchenne muscular dystrophy patients who are amenable to exon 51 skipping. The company is also developing PGN-EDODM1 for myotonic dystrophy type 1, a genetic neuromuscular disorder. These programs are intended to address diseases in which the delivery of therapeutic genetic material remains a significant challenge. Founded in 2018 and headquartered in Boston, Massachusetts, PepGen advances its candidates through clinical development and related research activities. The company’s programs are directed toward patients in markets where Duchenne muscular dystrophy, myotonic dystrophy and other rare neuromuscular conditions are treated, although product availability will depend on successful clinical development and regulatory approval.View PepGen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushGold Has Gone Sideways, But These 3 Stocks Haven’tLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in Focus Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
